Raghav Sundar: Understanding Resistance Mechanisms in HER2+ Gastric Cancer
Raghav Sundar, Leader Gastroesophageal Cancer Program, Associate Professor of Medicine (Oncology), Yale University School of Medicine and Yale Cancer Center, posted the following on X:
“Cancers develop resistance to targeted therapies. Most studies on acquired resistance have focused on tumor cells and not the microenvironment. We outline spatial mechanisms of resistance to trastuzumab and T-DXd in HER2+ Gastric Cancer.”
Authors: Taotao Sheng, Raghav Sundar, Supriya Srivastava, Xuewen Ong, Su Ting Tay, Haoran Ma, Tomoyuki Uchihara, Benedict Shi Xiang Lian, Takeshi Hagihara, Chang Xu, Shamaine Wei Ting Ho, Kie Kyon Huang, Angie Lay Keng Tan, Michelle Shu Wen NG, Ng Shi Ya Clara, Vincenzo Nasca, Chiara Carlotta Pircher, Giovanni Randon, Silvia Giordano, Simona Corso, Jeffrey Huey Yew Lum, Ming Teh, Jimmy Bok Yan So, Jessica Gasparello, Matteo Fassan, Filippo Pietrantonio, Patrick Tan
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023